Data / Drug companies / Allergan, Inc.
Allergan, Inc.: 76 products in the FDA NDC directory, labeler code 0456
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Allergan, Inc. (labeler code 0456) lists 76 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 45 prescription drugs, 31 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 24, 2023.
The request: Watch Allergan, Inc. (FDA labeler code 0456): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0456
- Products in commercial distribution
- 76
- Packages
- 99
- Finished drugs by generic name
- 12
- Prescription products
- 45
- Over the counter products
- 0
- Flagged as original packager
- 34 of 34 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 2
- Earliest marketing start
- April 1, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 37 | 48.7% |
| Drugs for further processing | 31 | 40.8% |
| Other unapproved drugs | 8 | 10.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 45 | 59.2% |
| Drugs for further processing | 31 | 40.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Thyroid, porcine | 8 | 4 |
| Levomilnacipran hydrochloride | 6 | 1 |
| Milnacipran hydrochloride | 5 | 6 |
| Nebivolol hydrochloride | 4 | 5 |
| Memantine hydrochloride and donepezil hydrochloride | 4 | 2 |
| Asenapine maleate | 3 | 3 |
| Citalopram | 3 | 31 |
| Linaclotide | 3 | 2 |
| Vilazodone hydrochloride | 3 | 13 |
| Escitalopram | 3 | 34 |
| Ceftaroline fosamil | 2 | 2 |
| Ceftazidime, avibactam | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 28 | 36.8% |
| Tablet, film coated | 20 | 26.3% |
| Capsule, extended release | 8 | 10.5% |
| Capsule | 8 | 10.5% |
| Capsule, gelatin coated | 6 | 7.9% |
| Powder, for solution | 3 | 3.9% |
| Kit | 3 | 3.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Fetzima | 0456-2200 | Kit | New drug applications (NDA) | March 24, 2023 |
| Linaclotide | 0456-1206 | Capsule, gelatin coated | Drugs for further processing | January 30, 2017 |
| Linzess | 0456-1203 | Capsule, gelatin coated | New drug applications (NDA) | January 30, 2017 |
| Memantine hydrochloride and donepezil hydrochloride | 0456-1222 | Capsule | Drugs for further processing | July 18, 2016 |
| Namzaric | 0456-1221 | Capsule | New drug applications (NDA) | July 18, 2016 |
| Memantine hydrochloride and donepezil hydrochloride | 0456-1208 | Capsule | Drugs for further processing | July 18, 2016 |
| Namzaric | 0456-1207 | Capsule | New drug applications (NDA) | July 18, 2016 |
| Asenapine maleate | 0456-2404 | Tablet | Drugs for further processing | December 30, 2014 |
| Saphris | 0456-2402 | Tablet | New drug applications (NDA) | December 30, 2014 |
| Avycaz | 0456-2700 | Powder, for solution | New drug applications (NDA) | December 26, 2014 |
| Memantine hydrochloride and donepezil hydrochloride | 0456-1238 | Capsule | Drugs for further processing | December 24, 2014 |
| Namzaric | 0456-1228 | Capsule | New drug applications (NDA) | December 24, 2014 |
| Memantine hydrochloride and donepezil hydrochloride | 0456-1215 | Capsule | Drugs for further processing | December 24, 2014 |
| Namzaric | 0456-1214 | Capsule | New drug applications (NDA) | December 24, 2014 |
| Asenapine maleate | 0456-2412 | Tablet | Drugs for further processing | September 30, 2013 |
| Saphris | 0456-2410 | Tablet | New drug applications (NDA) | September 30, 2013 |
| Asenapine maleate | 0456-2407 | Tablet | Drugs for further processing | September 30, 2013 |
| Saphris | 0456-2405 | Tablet | New drug applications (NDA) | September 30, 2013 |
| Fetzima | 0456-2280 | Capsule, extended release | New drug applications (NDA) | July 25, 2013 |
| Fetzima | 0456-2240 | Capsule, extended release | New drug applications (NDA) | July 25, 2013 |
| Fetzima | 0456-2220 | Capsule, extended release | New drug applications (NDA) | July 25, 2013 |
| Fetzima | 0456-2212 | Capsule, extended release | New drug applications (NDA) | July 25, 2013 |
| Fetzima | 0456-2202 | Kit | New drug applications (NDA) | July 25, 2013 |
| Linaclotide | 0456-1205 | Capsule, gelatin coated | Drugs for further processing | September 8, 2012 |
| Linaclotide | 0456-1204 | Capsule, gelatin coated | Drugs for further processing | September 8, 2012 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.